Ergomed signs Asarina trial pact to run its midstage PMDD test

U.K.-based trial services co Ergomed (LON: ERGO) has penned a deal with Swedish biotech Asarina Pharma for its Phase IIb trial of sepranolone in patients with premenstrual dysphoric disorder (PMDD).

Ergomed will run the multicenter, multinational midstage test, which is slated to kick off in 2017. The contract trial co, which often shares the risks and rewards of R&D with its clients, said that it will co-invest into the trial in return for an equity stake in Asarina, although exact financial terms were not disclosed.

Sepranolone is a first-in-class endogenous small molecule that acts as a GABA-A modulating steroid antagonist and is, according to the biotech, the first product developed exclusively for PMDD.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Dr. Miroslav Reljanovic, CEO of Ergomed, said: “We are delighted to be the co-development partner for Asarina as it embarks upon its Phase IIb clinical trial programme for Sepranolone which has the potential to be a first-in-class therapy for this serious disease. This further expands the number of pipeline opportunities where we share in the potential upside as a drug is successfully developed through leveraging our expertise and experience in providing clinical trial services to support such development.”

Peter Nordkild, CEO of Asarina, added: “We are pleased to announce our partnership with Ergomed to conduct our Phase IIb study for Sepranolone. Premenstrual dysphoric disorder is very debilitating for women who suffer from this disorder. We believe Ergomed is an excellent partner to help us advance this innovative therapy through the clinic and look forward to working with the team.”

The CRO, which has a market cap of around $54 million, has been helping a number of biotechs, including a Phase III with Cel-Sci ($CVM), Synta Pharmaceuticals ($SNTA) and Aeterna Zentaris ($AEZS), as well as earlier stage work with Ferrer. It was up 1.5% on Wednesday. 


Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.